GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Debt-to-EBITDA

Gilead Sciences (BUE:GILD) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gilead Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ARS0 Mil. Gilead Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ARS0 Mil. Gilead Sciences's annualized EBITDA for the quarter that ended in Mar. 2024 was ARS-14,261,840 Mil. Gilead Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Gilead Sciences's Debt-to-EBITDA or its related term are showing as below:

BUE:GILD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.76   Med: 2.37   Max: 7.6
Current: 6.1

During the past 13 years, the highest Debt-to-EBITDA Ratio of Gilead Sciences was 7.60. The lowest was 0.76. And the median was 2.37.

BUE:GILD's Debt-to-EBITDA is ranked worse than
84.83% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs BUE:GILD: 6.10

Gilead Sciences Debt-to-EBITDA Historical Data

The historical data trend for Gilead Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Debt-to-EBITDA Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.25 7.60 2.36 2.85 2.38

Gilead Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 2.53 1.93 2.41 -

Competitive Comparison of Gilead Sciences's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Gilead Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Debt-to-EBITDA falls into.



Gilead Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gilead Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(649078.001 + 8371229.008) / 3789056.003
=2.38

Gilead Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -14261840.244
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Gilead Sciences  (BUE:GILD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Gilead Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (BUE:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.